US Generic Drug Tariff Threat: Implications for Indian Pharma

Source: The post “US Generic Drug Tariff Threat: Implications for Indian Pharma” has been created based on “US Generic Drug Tariff Threat: Implications for Indian Pharma” published in “Indian Express” on 28 July 2026. US Generic Drug Tariff Threat: Implications for Indian Pharma.

UPSC Syllabus: GS 3 – Economy

Context: U.S.A President Donald Trump has proposed imposing 100% tariffs on generic drugs after two years and 200% thereafter to encourage pharmaceutical manufacturing in the U.S.A. Although such tariff proposals have largely remained unimplemented so far, they have created uncertainty for Indian pharmaceutical exporters, as the U.S.A is India’s largest pharmaceutical export market.

Importance of the Proposed Tariff for India’s Pharmaceutical Sector

1. U.S.A accounts for nearly 40% of India’s pharmaceutical exports, making it the country’s largest export destination for medicines.
2. Around 90% of India’s pharmaceutical exports to the U.S.A consist of generic medicines, making Indian companies particularly vulnerable to any tariff on generics.
3. In 2025, India exported pharmaceutical products worth $9.7 billion to the U.S.A.
4. The U.S.A imported pharmaceutical products worth $213 billion in 2025, including $94.1 billion worth of finished medicines, which includes generic drugs.
5. Any tariff on generic medicines could affect the competitiveness of Indian pharmaceutical companies in their largest overseas market.

Reasons behind Trump’s tariff proposal

1. The proposed tariffs are intended to encourage pharmaceutical companies to establish manufacturing facilities in the U.S.A.
2. Trump has stated that companies that do not manufacture in the U.S.A would face financial penalties through higher tariffs.
3. Similar tariff threats have previously been issued to attract investment into the U.S.A rather than being immediately implemented.
4. So far, pharmaceutical products have largely remained exempt from tariff measures introduced under various U.S.A trade laws.

Impact on Indian Pharmaceutical Companies

1. Tariff uncertainty is encouraging greater outbound investment by Indian pharmaceutical companies in the U.S.A.
2. Sun Pharmaceutical Industries announced the acquisition of Organon & Co. for $11.8 billion, making it the largest overseas acquisition by an Indian pharmaceutical company.
3. According to a Grant Thornton report, April 2026 recorded 103 mergers and acquisitions worth $18.7 billion, the highest monthly deal value since May 2022, driven largely by outbound transactions.
4. India’s outbound pharmaceutical investment to the U.S.A increased to $4.08 billion in FY26, compared with $3.44 billion in FY25 and $2.44 billion in FY24.
5. Several Indian pharmaceutical companies already operate FDA-approved manufacturing facilities in the U.S.A, including Sun Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Cipla and Dr. Reddy’s Laboratories.
6. Cipla is expanding manufacturing capacity in Massachusetts and New York.
7. Dr. Reddy’s Laboratories has indicated its willingness to expand U.S.A manufacturing if commercially viable.

Challenges in Relocating Generic Drug Manufacturing

1. Generic medicines operate on extremely thin profit margins, making large-scale relocation of production financially difficult.
2. Generic drug manufacturing depends on global supply chains, particularly for Active Pharmaceutical Ingredients (APIs).
3. A significant share of APIs continues to be sourced from India and China.
4. Building an entirely domestic U.S.A pharmaceutical supply chain would require substantial investment.
5. Increased domestic manufacturing in the U.S.A is likely to raise medicine prices for consumers.

Challenges for India

1. Continued tariff uncertainty may encourage greater relocation of investment and manufacturing from India to the U.S.A.
2. Higher tariffs, if implemented, could reduce the price competitiveness of Indian generic medicines in the U.S.A market.
3. Indian pharmaceutical companies may face higher compliance and investment costs to establish manufacturing facilities in the U.S.A.
4. Greater overseas investment could potentially reduce future manufacturing expansion within India.

Way Forward

1. Indian pharmaceutical companies should diversify their export markets to reduce excessive dependence on the U.S.A, which currently accounts for nearly 40% of India’s pharmaceutical exports.
2. The Government should strengthen domestic pharmaceutical manufacturing, particularly the production of Active Pharmaceutical Ingredients (APIs), to reduce supply chain vulnerabilities and improve global competitiveness.
3. Indian companies should adopt a balanced investment strategy by expanding manufacturing in the U.S.A where commercially viable while continuing to strengthen their manufacturing base in India.
4. India should continue engaging with the U.S.A through bilateral trade dialogue to ensure stable market access for affordable generic medicines and avoid disruptive tariff measures.
5. The pharmaceutical industry should focus on improving innovation, operational efficiency, and cost competitiveness to remain resilient against changing global trade policies and maintain its leadership in generic drug exports.

Conclusion: Although the proposed tariffs have not yet been implemented, they signal a policy push toward reshoring pharmaceutical manufacturing in the U.S.A India’s pharmaceutical industry must balance continued access to its largest export market with diversification of markets, strengthening domestic manufacturing, and strategic overseas investments to remain globally competitive.

Question: Examine the implications of the proposed U.S.A tariff on generic drugs for India’s pharmaceutical sector.

Source: Indian Express